ArticleMethods in molecular biology (Clifton, N.J.)2026
Synaptic Silencing with Transactivation of Tetanus Neurotoxin for Pathway-Selective Manipulation.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To selectively block specific brain circuits using viral vectors, two main approaches have been developed. The first involves injecting a single viral vector into the cell bodies of target neurons, followed by chemical or optogenetic stimulation at their axon terminals. The second method, known as the intersectional double viral vector technique, uses a retrograde vector injected at the axon terminals and an anterograde vector at the cell bodies of target neurons, along with systemic ligand administration. This chapter focuses on the second approach, which allows for the targeted expression of enhanced tetanus neurotoxin in specific neural pathways. This effectively disrupts their transmission by Tet transactivator system, leading to behavioral deficits in macaque monkeys. Additionally, this chemogenetic blocking technique can be combined with the DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) technique to inhibit multiple pathways within a single animal. This approach has the potential to significantly advance systems neuroscience research.
Indexed as
Identifiers
41273650What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.